About this trial
Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as a choice of debridement method, where both arms follow normal wound care practice in use of advanced wound care treatments.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
At least 18 years old.
The index wound (i.e. current episode of the wound or ulceration) has been present for greater than 4 weeks prior to SV 1 and has had less than 1 year of documented medical treatment, as of the subject's consent for the study participation.
The index wound is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1.
Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
Disqualifiers
The index ulcer will be the largest ulcer if two or more VLUs are present and will be the only one evaluated in the study. If other Ulcerations are present on the same leg, they must be more than 2cm distant from index ulcer.
Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool.
All wounds using the Sandy Grading System, except those in the exclusion criteria. (See Appendix A for definitions)
All wounds as per the CDC Surgical Wound Classification, with the exception of Class IV or dirty infected wounds, SSI - Deep incisional and organ space. (See Appendix A for definitions)
Trial design
Parallel
Treatments tested in this trial
Study Device Debridement
Devicedebritom+ water jet debridement
SOC Debridement
DeviceSharp Scalpel
Treatment groups
Trial outcomes
Primary outcomes
Wound Closure
Time to heal
Secondary outcomes
Complications
Incidence of all index wound-related complications (eg. cellulitis or Infection), hospitalization, wound recurrence
Advanced Wound Care Treatments
Number of successful advanced wound care treatments placed (eg. Negative Pressure Wound Therapy /grafts)
Cost
Cost of Treatment (including Advance Wound Care) and including any index wound-related, event-driven complications using patient records or Medicare reimbursement method.
Healed Proportion
Proportion of wounds completely healed
Other outcomes
Unhealed Proportion
Proportion of wounds not completely healed
PAR
Percent Area Reduction of Wound
AWC Failure
Number of failures in regard to advanced wound care treatments
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Medaxis, LLC
Lead sponsor
NAMSA
Collaborator